Exclusive Summary

• The original patent has long expired, meaning no IP barriers and enabling rapid international registration and commercialization for distributors.
• As the clinical gold standard and first-line treatment for PBC and gallstones, it benefits from massive, stable, and long-term global market demand.
• The unique 50mg low-dose specification provides a strong differentiated advantage, specifically targeting pediatric cholestasis patients and sensitive patient groups requiring precise dose titration, effectively avoiding the red ocean price war of standard 250mg products.
• Leveraging China's mature vertical integration from API to Finished Dosage Form (FDF), we can provide overseas distributors with highly competitive transfer prices and lucrative profit margins.